May 2024
1. WISCH JK, McKay NS, Boerwinkle AH, Kennedy J, et al
   Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional study.
   Lancet Neurol. 2024;23:500-510.
   

   >> Share

   
   
2. NORDBERG A
   Insights into the progression of genetic Alzheimer's disease from tau PET.
   Lancet Neurol. 2024;23:453-454.
   

   >> Share

   
   March 2024
3. FRISONI GB, Festari C, Massa F, Cotta Ramusino M, et al
   European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders.
   Lancet Neurol. 2024;23:302-312.
   

   >> Share

   
   
4. THE LANCET NEUROLOGY
   Dementia diagnosis in the anti-amyloid era.
   Lancet Neurol. 2024;23:219.
   

   >> Share

   
   February 2024
5. CHAPLEAU M, La Joie R, Yong K, Agosta F, et al
   Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis.
   Lancet Neurol. 2024;23:168-177.
   

   >> Share

   
   
6. REIMAN EM, Cummings JL, Langbaum JB, Mattke S, et al
   A chance to prevent Alzheimer's disease sooner than you think.
   Lancet Neurol. 2024;23:144-145.
   

   >> Share

   
   
7. BEJANIN A, Villain N
   Posterior cortical atrophy: new insights into treatments and biomarkers for Alzheimer's disease.
   Lancet Neurol. 2024;23:127-128.
   

   >> Share

   
   January 2024
8. DELRIEU J, Andrieu S, Vellas B
   Dementia research in 2023: the year of anti-amyloid immunotherapy.
   Lancet Neurol. 2024;23:13-15.
   

   >> Share

   
   December 2023
9. RANSCOMBE P
   Powerful series profiles rare forms of dementia.
   Lancet Neurol. 2023;22:1112.
   

   >> Share

   
   November 2023
10. SCHLEPCKOW K, Morenas-Rodriguez E, Hong S, Haass C, et al
    Stimulation of TREM2 with agonistic antibodies-an emerging therapeutic option for Alzheimer's disease.
    Lancet Neurol. 2023;22:1048-1060.
    

    >> Share

    
    September 2023
11. JAGUST WJ, Teunissen CE, DeCarli C
    The complex pathway between amyloid beta and cognition: implications for therapy.
    Lancet Neurol. 2023;22:847-857.
    

    >> Share

    
    July 2023
12. BELDER CRS, Schott JM, Fox NC
    Preparing for disease-modifying therapies in Alzheimer's disease.
    Lancet Neurol. 2023 Jul 14:S1474-4422(23)00274.
    

    >> Share

    
    
13. FRISONI GB
    Complexity is the simple truth about Alzheimer's disease.
    Lancet Neurol. 2023 Jul 13:S1474-4422(23)00176.
    

    >> Share

    
    June 2023
14. THE LANCET NEUROLOGY
    Treatment for Alzheimer's disease: time to get ready.
    Lancet Neurol. 2023;22:455.
    

    >> Share

    
    
15. MASON M, Bacioglu M, Vivacqua G, Spillantini MG, et al
    Targeting tau degradation: a viable therapeutic approach?
    Lancet Neurol. 2023;22:462-464.
    

    >> Share

    
    May 2023
16. LANGWORTH-GREEN C, Patel S, Jaunmuktane Z, Jabbari E, et al
    Chronic effects of inflammation on tauopathies.
    Lancet Neurol. 2023;22:430-442.
    

    >> Share

    
    February 2023
17. MEAD S, Fox NC
    Lecanemab slows Alzheimer's disease: hope and challenges.
    Lancet Neurol. 2023;22:106-108.
    

    >> Share

    
    January 2023
18. BOERWINKLE AH, Gordon BA, Wisch J, Flores S, et al
    Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study.
    Lancet Neurol. 2023;22:55-65.
    

    >> Share

    
    
19. FORTEA J, Quiroz YT, Ryan NS
    Lessons from Down syndrome and autosomal dominant Alzheimer's disease.
    Lancet Neurol. 2023;22:5-6.
    

    >> Share

    
    November 2022
20. HARDY J, de Strooper B, Escott-Price V
    Diabetes and Alzheimer's disease: shared genetic susceptibility?
    Lancet Neurol. 2022;21:962-964.
    

    >> Share

    
    October 2022
21. JACK CR JR
    Advances in Alzheimer's disease research over the past two decades.
    Lancet Neurol. 2022;21:866-869.
    

    >> Share

    
    May 2022
22. OSSENKOPPELE R, van der Kant R, Hansson O
    Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials.
    Lancet Neurol. 2022 May 25. pii: S1474-4422(22)00168.
    

    >> Share

    
    April 2022
23. MORENAS-RODRIGUEZ E, Li Y, Nuscher B, Franzmeier N, et al
    Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study.
    Lancet Neurol. 2022;21:329-341.
    

    >> Share

    
    
24. SMIRNOV D, Galasko D
    Dynamics of neuroinflammation in Alzheimer's disease.
    Lancet Neurol. 2022;21:297-298.
    

    >> Share

    
    February 2022
25. CHHATWAL JP, Schultz SA, McDade E, Schultz AP, et al
    Variant-dependent heterogeneity in amyloid beta burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study.
    Lancet Neurol. 2022;21:140-152.
    

    >> Share

    
    
26. FRISONI GB, Lathuiliere A
    From patients to disease: the difficult case of Alzheimer's.
    Lancet Neurol. 2022;21:105-106.
    

    >> Share

    
    January 2022
27. KANTARCI K
    2021 marks a new era for Alzheimer's therapeutics.
    Lancet Neurol. 2022;21:3-4.
    

    >> Share

    
    December 2021
28. MEAD S, Evans T
    Safe laboratory management of prions and proteopathic seeds.
    Lancet Neurol. 2021;20:981.
    

    >> Share

    
    November 2021
29. TEUNISSEN CE, Verberk IMW, Thijssen EH, Vermunt L, et al
    Blood-based biomarkers for Alzheimer's disease: towards clinical implementation.
    Lancet Neurol. 2021 Nov 24. pii: S1474-4422(21)00361.
    

    >> Share

    
    
30. FORTEA J, Zaman SH, Hartley S, Rafii MS, et al
    Alzheimer's disease associated with Down syndrome: a genetic form of dementia.
    Lancet Neurol. 2021;20:930-942.
    

    >> Share

    
    
31. KEHOE PG, Turner N, Howden B, Jarutyte L, et al
    Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial.
    Lancet Neurol. 2021;20:895-906.
    

    >> Share

    
    
32. DECARLI C
    The link between blood pressure and Alzheimer's disease.
    Lancet Neurol. 2021;20:878-879.
    

    >> Share

    
    September 2021
33. THIJSSEN EH, La Joie R, Strom A, Fonseca C, et al
    Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study.
    Lancet Neurol. 2021;20:739-752.
    

    >> Share

    
    
34. PARNETTI L, Filippo MD, Gaetani L
    A blood test for Alzheimer's disease: a step forward.
    Lancet Neurol. 2021;20:691-693.
    

    >> Share

    
    August 2021
35. FAGAN AM, Henson RL, Li Y, Boerwinkle AH, et al
    Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study.
    Lancet Neurol. 2021;20:615-626.
    

    >> Share

    
    
36. FRISONI GB, Hansson O
    Management of Alzheimer's disease takes a leap forward.
    Lancet Neurol. 2021;20:586-587.
    

    >> Share

    
    
37. CARMONA-IRAGUI M, Alcolea D, Barroeta I, Videla L, et al
    Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study.
    Lancet Neurol. 2021;20:605-614.
    

    >> Share

    
    July 2021
38. THE LANCET NEUROLOGY
    A contentious FDA ruling for Alzheimer's disease.
    Lancet Neurol. 2021 Jul 5. pii: S1474-4422(21)00215.
    

    >> Share

    
    
39. BURNS DK, Alexander RC, Welsh-Bohmer KA, Culp M, et al
    Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial.
    Lancet Neurol. 2021;20:537-547.
    

    >> Share

    
    April 2021
40. DUBOIS B, Villain N, Frisoni GB, Rabinovici GD, et al
    Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group.
    Lancet Neurol. 2021 Apr 29. pii: S1474-4422(21)00066.
    

    >> Share

    
    
41. JAGUST WJ
    The changing definition of Alzheimer's disease.
    Lancet Neurol. 2021 Apr 29. pii: S1474-4422(21)00077.
    

    >> Share

    
    March 2021
42. GRAFF-RADFORD J, Yong KXX, Apostolova LG, Bouwman FH, et al
    New insights into atypical Alzheimer's disease in the era of biomarkers.
    Lancet Neurol. 2021;20:222-234.
    

    >> Share

    
    January 2021
43. SERRANO-POZO A, Das S, Hyman BT
    APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches.
    Lancet Neurol. 2021;20:68-80.
    

    >> Share

    
    
44. KIVIPELTO M, Mangialasche F
    Dementia research in 2020: moving forward despite the COVID-19 pandemic.
    Lancet Neurol. 2021;20:3-5.
    

    >> Share

    
    
45. THE LANCET NEUROLOGY
    Rapid drug access and scientific rigour: a delicate balance.
    Lancet Neurol. 2021;20:1.
    

    >> Share

    
    November 2020
46. CHETELAT G, Arbizu J, Barthel H, Garibotto V, et al
    Amyloid-PET and (18)F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias.
    Lancet Neurol. 2020;19:951-962.
    

    >> Share

    
    
47. ISAACS JD, Boenink M
    Biomarkers for dementia: too soon for routine clinical use.
    Lancet Neurol. 2020;19:884-885.
    

    >> Share

    
    October 2020
48. LAUWERS E, Lalli G, Brandner S, Collinge J, et al
    Potential human transmission of amyloid beta pathology: surveillance and risks.
    Lancet Neurol. 2020;19:872-878.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share